Tag Archives: immunai ai schusterman foundationwiggersventurebeat

Immunai, a New York-based biotech company, has recently secured $60 million in Series A funding to further develop its cutting-edge artificial intelligence (AI) platform for immune profiling. The funding round was led by Schusterman Foundation and Wiggers VentureBeat, with participation from several other prominent investors. Immunai’s innovative approach aims to …

Read More »